Haemopoietic-cell transplantation (HCT) is an intensive therapy used to treat high-risk
haematological malignant disorders and other life-threatening haematological and genetic …

This consensus statement established under the auspices of the German working group on
BM and blood stem cell transplantation (DAG-KBT), the German Society of Hematology and …

Abstract The 2006 National Institutes of Health (NIH) Consensus paper presented
recommendations by the Ancillary Therapy and Supportive Care Working Group to support …

Bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation
(HCT) is associated with high mortality. We hypothesized that inhaled fluticasone …

Chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell
transplantation is still associated with significant morbidity and mortality. First-line treatment …

Bronchiolitis obliterans syndrome (BOS) is a progressive, insidious, and often fatal lung
alloreaction that can occur following allogeneic hematopoietic stem cell transplantation …

This review is the summary of a workshop on small airways disease, which took place in
Porquerolles, France in November 2011. The purpose of this workshop was to review the …

In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic
hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of …

More than 25 000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are
expected to be performed worldwide in 2010, a number that has been increasing yearly …

Bronchiolitis obliterans syndrome (BOS) is a devastating pulmonary complication affecting
long-term survivors of allogeneic hematopoietic cell transplantation. Treatment of BOS with …